Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
At a glance
- Drugs ABT 165 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors AbbVie
- 21 Nov 2018 Planned primary completion date changed from 24 Feb 2020 to 21 Aug 2020.
- 16 Nov 2018 Planned End Date changed from 24 Feb 2020 to 21 Aug 2020.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology